Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients.
Aged
Antibodies, Viral
/ immunology
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
Female
Humans
Immunoglobulin G
/ immunology
Lymphocyte Count
Male
Middle Aged
Monocytes
/ immunology
Prospective Studies
SARS-CoV-2
/ immunology
Severity of Illness Index
Autoimmunity ⋅ B/T-cell ratio ⋅ COVID-19 ⋅ Lymphocytes ⋅ Monocytes
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
30
01
2021
received:
29
12
2020
accepted:
22
03
2021
pubmed:
1
4
2021
medline:
16
6
2021
entrez:
31
3
2021
Statut:
ppublish
Résumé
The pathogenesis of autoimmune complications triggered by SARS-CoV2 has not been completely elucidated. Here, we performed an analysis of the cellular immune status, cell ratios, and monocyte populations of patients with COVID-19 treated in the intensive care unit (ICU) (cohort 1, N = 23) and normal care unit (NCU) (cohort 2, n = 10) compared with control groups: patients treated in ICU for noninfectious reasons (cohort 3, n = 30) and patients treated in NCU for infections other than COVID-19 (cohort 4, n = 21). Patients in cohort 1 presented significant differences in comparison with the other cohorts, including reduced frequencies of lymphocytes, reduced CD8+T-cell count, reduced percentage of activated and intermediate monocytes and an increased B/T8 cell ratio. Over time, patients in cohort 1 who died presented with lower counts of B, T, CD4
Identifiants
pubmed: 33788264
doi: 10.1002/eji.202049163
pmc: PMC8250224
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1449-1460Subventions
Organisme : the Rolf M. Schwiete Stiftung, the Saarland University, and the State of Saarland (CORSAAR)
Informations de copyright
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Blood. 2020 May 21;135(21):1912-1915
pubmed: 32302379
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
JCI Insight. 2020 Oct 15;5(20):
pubmed: 32937615
Eur J Immunol. 2020 Dec;50(12):2013-2024
pubmed: 33080068
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Int J Infect Dis. 2020 Sep;98:353-358
pubmed: 32634585
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Front Oncol. 2020 Sep 02;10:1578
pubmed: 32984017
Immunology. 2020 Dec;161(4):345-353
pubmed: 32870529
Medicine (Baltimore). 2019 Jul;98(29):e16535
pubmed: 31335735
Ann Intensive Care. 2017 Dec;7(1):30
pubmed: 28303547
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Cell Death Dis. 2020 Jun 8;11(6):429
pubmed: 32513989
Blood Cells Mol Dis. 2020 Jul;83:102437
pubmed: 32325421
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803